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Background
Evidence suggests that gut flora may play an important role in the pathophysiology 
of the irritable bowel syndrome (IBS). We evaluated rifaximin, a minimally ab-
sorbed antibiotic, as treatment for IBS.
Methods
In two identically designed, phase 3, double-blind, placebo-controlled trials 
(TARGET 1 and TARGET 2), patients who had IBS without constipation were ran-
domly assigned to either rifaximin at a dose of 550 mg or placebo, three times 
daily for 2 weeks, and were followed for an additional 10 weeks. The primary end 
point, the proportion of patients who had adequate relief of global IBS symptoms, 
and the key secondary end point, the proportion of patients who had adequate relief 
of IBS-related bloating, were assessed weekly. Adequate relief was defined as self-
reported relief of symptoms for at least 2 of the first 4 weeks after treatment. 
Other secondary end points included the percentage of patients who had a response 
to treatment as assessed by daily self-ratings of global IBS symptoms and individual 
symptoms of bloating, abdominal pain, and stool consistency during the 4 weeks 
after treatment and during the entire 3 months of the study.
Results
Significantly more patients in the rifaximin group than in the placebo group had 
adequate relief of global IBS symptoms during the first 4 weeks after treatment 
(40.8% vs. 31.2%, P = 0.01, in TARGET 1; 40.6% vs. 32.2%, P = 0.03, in TARGET 2; 
40.7% vs. 31.7%, P<0.001, in the two studies combined). Similarly, more patients in 
the rifaximin group than in the placebo group had adequate relief of bloating 
(39.5% vs. 28.7%, P = 0.005, in TARGET 1; 41.0% vs. 31.9%, P = 0.02, in TARGET 2; 
40.2% vs. 30.3%, P<0.001, in the two studies combined). In addition, significantly 
more patients in the rifaximin group had a response to treatment as assessed by 
daily ratings of IBS symptoms, bloating, abdominal pain, and stool consistency. 
The incidence of adverse events was similar in the two groups.
Conclusions
Among patients who had IBS without constipation, treatment with rifaximin for 
2 weeks provided significant relief of IBS symptoms, bloating, abdominal pain, and 
loose or watery stools. (Funded by Salix Pharmaceuticals; ClinicalTrials.gov num-
bers, NCT00731679 and NCT00724126.)
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The irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurring symptoms of 
abdominal pain, bloating, and altered bowel func-
tion in the absence of structural, inflammatory, 
or biochemical abnormalities.1 IBS often does not 
respond to current treatment options, including 
dietary and lifestyle modifications, fiber supple-
mentation, psychological therapy, and pharmaco-
therapy.2,3 Because no reliable biologic or struc-
tural markers have been identified, the effects of 
pharmacotherapy are typically assessed by ask-
ing patients to report whether they had adequate 
relief of IBS symptoms (with a binary response of 
yes or no).4 Given the limitations of available 
therapies, there is an unmet medical need for 
novel therapeutic approaches.
Patients with IBS may have alterations in the 
intestinal microbiota,5-7 thus leading investigators 
to consider targeting the intestinal microbiota for 
the treatment of this condition. Although some 
patients have had improvement with neomycin 
therapy, clinical trials have shown that it has 
marginal efficacy, and side effects limit the use 
of the drug.8 The use of systemic antibiotics has 
been reported with mixed results.9
Rifaximin (Xifaxan, Salix Pharmaceuticals) is 
an oral, nonsystemic, broad-spectrum antibiotic 
that targets the gut and is associated with a low 
risk of bacterial resistance.10-12 It has shown ef-
ficacy in small-scale studies of IBS.13,14 We pre-
sent the results of two large-scale, identically 
designed, multicenter trials — TARGET 1 and 
TARGET 2 — of 3 months’ duration that exam-




Eligible patients were at least 18 years of age; had 
undergone a colonoscopic examination within the 
previous 2 years; had received a diagnosis of and 
had current symptoms of IBS (as assessed accord-
ing to the Rome II diagnostic criteria for IBS15), 
in particular, symptoms of abdominal pain and 
discomfort; and did not have adequate relief of 
global IBS symptoms and of IBS-related bloating 
at both the time of screening and the time of 
randomization. Eligible patients rated the aver-
age daily amount of abdominal pain and of bloat-
ing as a score of 2 to 4.5 on a 7-point Likert scor-
ing system (with 0 indicating not at all; 1, hardly; 
2, somewhat; 3, moderately; 4, a good deal; 5, a 
great deal; and 6, a very great deal) and rated the 
average daily consistency of their stools as 3.5 or 
more on a 5-point scale for stool consistency 
(with 1 indicating very hard; 2, hard; 3, formed; 
4, loose; and 5, watery) over the course of at least 
7 days.
Exclusion criteria were constipation-predom-
inant IBS (according to the definition in the 
Rome II criteria15), a history of inflammatory 
bowel disease, diabetes, unstable thyroid disease, 
previous abdominal surgery (other than chole-
cystectomy or appendectomy), human immuno-
deficiency virus infection, and renal or hepatic 
disease. Patients were excluded if they were cur-
rently taking alosetron, tegaserod, lubiprostone, 
warfarin, or antipsychotic, antispasmodic, anti-
diarrheal, probiotic, or narcotic drugs or if they 
had taken antibiotics within the previous 14 days 
or rifaximin within 60 days before signing the 
informed-consent form for the study. Patients 
were allowed to take antidepressant agents of 
the selective serotonin-reuptake inhibitor and 
tricyclic antidepressant classes, provided that they 
had been taking a stable dose for at least 6 weeks. 
All patients provided written informed consent 
before study-related procedures were initiated.
Study Design and Procedures
The protocols were approved by the institutional 
review board or independent ethics committee 
at each center, and the studies were conducted in 
accordance with applicable laws and regulations 
(see the Supplementary Appendix, available with 
the full text of this article at NEJM.org). After a 
screening phase of 7 to 13 days, eligible patients 
were randomly assigned with the use of an inter-
active voice-response system to either rifaximin 
or placebo, in a 1:1 ratio. The randomization code 
was computer-generated, and randomization was 
performed in blocks of four, stratified according 
to center. After completing the 14-day study-
treatment period, patients were evaluated for 10 
additional weeks. Study visits were conducted on 
days 1, 7, 14, 28, and 84, and patients were mon-
itored by means of telephone calls on days 42, 56, 
and 70. Efficacy assessments were obtained daily 
by means of an interactive voice-response system 
over the course of the entire study (Fig. 1).
The protocol was designed by Salix Pharma-
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thors. Data were collected by investigators at 
each center (see the Supplementary Appendix) 
and were monitored by Quintiles (a contract re-
search organization) under the supervision of 
Salix Pharmaceuticals. The data were analyzed 
by personnel at Salix Pharmaceuticals, in collabo-
ration with the academic authors. All the authors 
participated in the interpretation of the data and 
in the writing of the manuscript. The first two 
authors wrote the first draft of the manuscript, 
and all the authors, in addition to an employee 
of Salix, assisted in the revision of subsequent 
drafts. All the authors made the decision to sub-
mit the manuscript for publication. The trial pro-
tocol, including the statistical analysis plan, is 
available at NEJM.org. All the authors vouch for 
the completeness and veracity of the data and 
analyses, as well as the fidelity of this report to 
the trial protocol.
Efficacy and Safety End Points
The primary end point was the proportion of 
patients who had adequate relief of global IBS 
symptoms for at least 2 of the 4 weeks during the 
primary evaluation period (weeks 3 through 6). 
This end point was determined from the response 
(yes or no) to the following question, which was 
asked weekly: “In regard to all your symptoms of 
IBS, as compared with the way you felt before you 
started the study medication, have you, in the 
past 7 days, had adequate relief of your IBS symp-
toms?” The threshold for clinical relevance — 
adequate relief during at least 2 weeks per month 
— was defined prospectively. In addition, the 
proportion of patients who reported that they 
had adequate relief during at least 2 weeks per 
month (“monthly response”) during months 1, 2, 
and 3 was assessed to identify the onset and du-
ration of the therapeutic effect. Patients who 
started to take antibiotics (other than the study 
medication) or who took more than two doses of 
a medication that was prohibited per the study 
protocol were considered not to have had a re-
sponse to treatment starting from the time the 
medication was initiated, regardless of their re-
sponse data.
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Figure 1. Study Design.
The TARGET 1 and TARGET 2 studies had the same study design. There was a screening period of 7 to 13 days be-
fore randomization (day 1). Study visits occurred on days 1, 7, 14, 28, and 84; patients were monitored by means of 
telephone calls on days 42, 56, and 70 (telephone symbols). Triangles indicate the days on which the efficacy and 
safety end points were assessed (except in the case of daily symptoms of irritable bowel syndrome [IBS], which were 
assessed every day).
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The key secondary end point, the proportion 
of patients who had adequate relief of IBS-related 
bloating during the primary evaluation period, 
was determined from the response (yes or no) to 
the weekly question, “In regard to your symp-
toms of bloating, as compared with the way you 
felt before you started study medication, have 
you, in the past 7 days, had adequate relief of 
your IBS symptom of bloating?” The onset and 
duration of relief of bloating were also assessed 
in an analysis of monthly response, as described 
above for the primary end point.
For other secondary end points, the propor-
tion of patients who had relief was determined 
from the patients’ daily assessments of IBS symp-
toms, bloating, and abdominal pain and discom-
fort (as rated on a 7-point scale); relief was de-
fined as a score of either 0 (not at all) or 1 (hardly) 
for at least 50% of the days in a given week or a 
score of 0 (not at all), 1 (hardly), or 2 (somewhat) 
for 100% of the days in a given week for at least 
2 of the 4 weeks during a given month.
An exploratory end point, which was included 
at the request of the Food and Drug Administra-
tion (FDA), was the proportion of patients who 
had relief of the composite of abdominal pain 
and discomfort and loose or watery stools (as 
measured by improvement in stool consistency), 
on the basis of daily assessments. Relief was de-
fined as a decrease of at least 30% from baseline 
in weekly mean ratings of IBS-related abdominal 
pain or discomfort and a weekly mean stool-
consistency score of less than 4 (with 4 indicat-
ing loose stools and lower scores indicating more 
formed stools) for at least 2 of the 4 weeks dur-
ing a given month. This exploratory end point is 
consistent with the recommended composite end 
point for IBS with diarrhea in a recently released 
draft of FDA guidelines.16 Safety assessments in-
cluded the monitoring of adverse events, results 
of clinical laboratory testing, findings from 
physical examinations, and vital signs.
Statistical Analysis
We estimated the sample size for each study as-
suming that 40% of the patients in the placebo 
group and 55% in the rifaximin group would 
meet the criteria for the primary end point (i.e., 
would have adequate relief of global IBS symp-
toms, as assessed weekly) for at least 2 of the 
first 4 weeks after treatment. With these as-
sumptions, a sample of 300 patients would be 
needed in each group for the studies to have 95% 
power to show the 15-percentage-point differ-
ence between the groups, at a significance level 
of 0.05.
All efficacy and safety analyses were per-
formed on a modified intention-to-treat popula-
tion, which included all patients who received at 
least one dose of the study drug. Missing data 
were imputed with the use of the last-observation-
carried-forward method, whereby missing values 
were replaced with the last nonmissing value; 
baseline values were not carried forward. Two 
sensitivity analyses were conducted, one in which 
missing data were regarded as indicating that 
the patients who terminated the study prema-
turely had had no relief of symptoms, and the 
other in which missing data were imputed with 
the use of the multiple-imputation method.
Binary data (i.e., data on the proportion of 
patients who had or did not have adequate relief 
of symptoms) were analyzed with the use of lo-
gistic regression; fixed-effect terms included the 
study group and the analysis center. There were 
five analysis centers, which we formed prospec-
tively by grouping the study centers according to 
geographic region in order to assess the effects 
of geographic location on the end points. For the 
analysis of ordinal data (i.e., data on the number 
of months in which patients had relief for at 
least 2 weeks per month), we used the propor-
tional-odds model for the ordinal outcome. The 
number of consecutive months with relief during 
the first 3 months after treatment was summed 
for each patient, so that each patient received a 
score of 0, 1, 2, or 3.
We analyzed the changes from baseline in 
continuous outcomes (i.e., symptom scores) by 
fitting fixed-effects linear models to the data. 
An initial model with terms for treatment, 
analysis center, baseline ratings of the response 
variable, and interaction of baseline ratings with 
treatment was fitted. The interaction term was 
tested at the 0.05 level. A nonsignificant interac-
tion was dropped from the model in subsequent 
analyses.
Spearman correlation analyses were applied to 
the mean change from baseline in daily assess-
ments of adequate relief of IBS symptoms (yes or 
no) to determine whether the weekly assessments 
of adequate relief paralleled the pattern seen with 
the daily assessments. Safety data were summa-
rized with the use of descriptive statistics.
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R esult s
Study Patients
A total of 1260 patients who had IBS without 
constipation were enrolled in the studies (623 pa-
tients in TARGET 1 and 637 in TARGET 2) and 
underwent randomization at one of 179 investi-
gative sites in the United States (1217 patients) 
and Canada (43 patients) (Fig. 2). The studies 
were conducted in parallel from June 2008 
through August 2009. In TARGET 1, all the pa-
tients who underwent randomization took at 
least one dose of the study drug. In TARGET 2, 
two patients (one in each group) underwent ran-
domization but did not receive a study drug. 
Thus, 1258 patients received at least one dose of 
the study drug and were included in the modified 
intention-to-treat population. More than 90% of 
the patients completed the entire 12-week study. 
The baseline characteristics of the patients were 
similar in the two studies and across treatment 
groups (Table 1). The rate of adherence to the 
study drug, defined as the use of at least 70% of 
the dispensed tablets, was at least 97% in both 
study groups in both studies.
Efficacy during the Primary Evaluation 
Period (Weeks 3 through 6)
Adequate Relief of Global IBS Symptoms
Significantly more patients in the rifaximin group 
than in the placebo group met the criteria for the 
primary end point of adequate relief of global IBS 
symptoms for at least 2 of the first 4 weeks after 
treatment (40.8% vs. 31.2%, P = 0.01, in TARGET 1; 
40.6% vs. 32.2%, P = 0.03, in TARGET 2; 40.7% 
vs. 31.7%, P<0.001, in the two studies combined) 
(Fig. 3A). The last-observation-carried-forward 
method was applied in the case of 5.8% of the 
patients in the rifaximin group and 5.7% of the 
patients in the placebo group in TARGET 1 and 
in the case of 5.4% in the rifaximin group and 
8.4% in the placebo group in TARGET 2. Overall, 
1260 Patients were enrolled
637 Were assigned to Target 2623 Were assigned to Target 1
321 Were assigned to receive
placebo
19 Discontinued study
2 Had adverse event
8 Withdrew
6 Were lost to
follow-up
2 Did not adhere to
regimen
1 Had other reason
320 Were included in the
modified intention-to-treat
analysis
309 Were assigned to receive
rifaximin
26 Discontinued study
8 Had adverse event
8 Withdrew
8 Were lost to
follow-up
1 Did not adhere to
regimen
1 Was pregnant
309 Were included in the
modified intention-to-treat
analysis
314 Were assigned to receive
placebo
22 Discontinued study
7 Had adverse event
8 Withdrew
7 Were lost to
follow-up
314 Were included in the
modified intention-to-treat
analysis




6 Were lost to
follow-up
1 Did not adhere to
regimen
2 Had other reason
315 Were included in the
modified intention-to-treat
analysis
Figure 2. Enrollment, Randomization, and Follow-up in the TARGET 1 and TARGET 2 Studies.
A total of 92.3% of the patients in TARGET 1 and 94.7% of the patients in TARGET 2 completed the study. Two patients from TARGET 2, 
one in each study group, were excluded from the analysis because they did not take the study drug. Thus, 1258 patients in TARGET 2 re-
ceived at least one dose of the study drug and were included in the modified intention-to-treat analysis.
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sensitivity analyses that were performed to ad-
dress the effect of missing values yielded results 
that were consistent with those of the primary 
efficacy analysis (see the Supplementary Appen-
dix). On the basis of daily assessments of IBS 
symptoms, the proportion of patients with a re-
sponse to treatment, as rated on a 7-point scale 
during the primary evaluation period, was sig-
nificantly greater in the rifaximin group than in 
the placebo group (42.7% vs. 30.6%, P<0.001, in 
TARGET 1; 37.8% vs. 28.4%, P = 0.007, in TARGET 
2; 40.2% vs. 29.5%, P<0.001, in the two studies 
combined) (Fig. 3A).
Adequate Relief of IBS-Related Bloating
Significantly more patients in the rifaximin group 
than in the placebo group met the criteria for the 
key secondary end point, adequate relief of IBS-
related bloating for at least 2 of the first 4 weeks 
after treatment (39.5% vs. 28.7%, P = 0.005, in 
TARGET 1; 41.0% vs. 31.9%, P = 0.02, in TARGET 
2; 40.2% vs. 30.3%, P<0.001, in the two studies 
combined) (Fig. 3A). Sensitivity analyses that were 
performed to assess the effect of missing values 
yielded similar results (see the Supplementary Ap-
pendix). On the basis of daily assessments of IBS-
related bloating as rated on a 7-point scale during 
Table 1. Demographic and Baseline Characteristics of the Modified Intention-to-Treat Population in the Two Studies.*








(N = 320) P Value†
Age — yr 46.2±15.0 45.5±14.6 0.55 45.9±13.9 46.3±14.6 0.72
Age group — no. (%) 0.71 0.44
<65 yr 275 (89.0) 276 (87.9) 285 (90.5) 283 (88.4)
≥65 yr 34 (11.0) 38 (12.1) 30 (9.5) 37 (11.6)
Sex — no. (%) 0.15 0.66
Male 74 (23.9) 92 (29.3) 88 (27.9) 95 (29.7)
Female 235 (76.1) 222 (70.7) 227 (72.1) 225 (70.3)
Race — no. (%)‡ 0.50 0.08
Black or of African ancestry 24 (7.8) 30 (9.6) 21 (6.7) 14 (4.4)
White 281 (90.9) 280 (89.2) 282 (89.5) 302 (94.4)
Other 4 (1.3) 4 (1.3) 12 (3.8) 4 (1.2)
Average daily scores
Global IBS symptoms§ 3.4±0.7 3.4±0.7 0.47 3.4±0.7 3.4±0.7 0.53
IBS-related bloating§ 3.3±0.8 3.3±0.7 0.43 3.2±0.7 3.3±0.7 0.28
Abdominal pain and discomfort§ 3.3±0.7 3.2±0.7 0.75 3.3±0.7 3.3±0.7 0.69
Stool consistency¶ 3.9±0.3 3.9±0.3 0.18 3.9±0.3 3.9±0.3 0.80
Average daily bowel movements — no. 2.9±1.3 3.0±1.4 0.27 3.0±1.6 3.0±1.5 0.78
Days with stool urgency — %‖ 81.8±22.3 82.9±22.3 0.53 81.3±22.8 82.2±22.5 0.64
Duration of IBS symptoms — yr** 11.9±10.5 11.4±11.9 0.61 10.8±10.2 11.8±10.4 0.19
*  Plus–minus values are means ±SD. IBS denotes irritable bowel syndrome.
†  P values were calculated with the use of a t-test for continuous variables and Fisher’s exact test for nominal variables.
‡  Race was self-reported.
§  Patients were asked to rate how bothersome their symptoms were on that day, on a scale of 0 to 6. A score of 0 indicated not at all; 1, 
hardly; 2, somewhat; 3, moderately; 4, a good deal; 5, a great deal; and 6, a very great deal.
¶  Patients were asked to rate the overall stool form of their bowel movements on that day. A score of 1 indicated very hard; 2, hard; 3, 
formed; 4, loose; and 5, watery.
‖  The percentage of days with stool urgency was calculated with the use of the following formula: 100 × (no. of days with a sense of urgency 
with any of the bowel movements ÷ no. of days with bowel movements).
** The duration of IBS symptoms was calculated with the use of the following formula: (date written informed consent was provided − date of 
first IBS symptom) ÷ 365.25.
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the same primary evaluation period, a significant-
ly greater proportion of patients in the rifaximin 
group than in the placebo group had relief (39.2% 
vs. 32.5%, P = 0.05, in TARGET 1; 43.5% vs. 30.9%, 
P<0.001, in TARGET 2; 41.3% vs. 31.7%, P<0.001, 
in the two studies combined) (Fig. 3A).
Relief of IBS-Related Abdominal Pain and Loose 
or Watery Stools
A significantly greater proportion of patients in 
the rifaximin group than in the placebo group 
had relief of IBS-related abdominal pain and dis-
comfort during the primary evaluation period 
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Figure 3. Analyses of Primary, Key Secondary, and Other Secondary End Points.
The odds ratios for relief of symptoms during the primary evaluation period (weeks 3 through 6 of the study) (Panel A) and for the entire 
3-month study period (Panel B) are shown for the modified intention-to-treat population (with the use of the last-observation-carried-
forward approach). Two patients from TARGET 2, one in each study group, were excluded from the analysis because they did not take 
the study drug. The analyses were performed on data from weekly or daily assessments of symptoms, as noted. The analyses of the 
composite end point of abdominal pain and stool consistency and of the two components of that composite end point were exploratory 
end points requested by the Food and Drug Administration.
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(44.3% vs. 36.3%, P = 0.03, in TARGET 1; 42.9% 
vs. 34.4%, P = 0.02, in TARGET 2) (Fig. 3A). In an 
assessment of the composite end point of ab-
dominal pain or discomfort and loose or watery 
stools, significantly more patients in the rifaxi-
min group than in the placebo group had relief 
during the primary evaluation period (46.6% vs. 
38.5%, P = 0.04, in TARGET 1; 46.7% vs. 36.3%, 
P = 0.008, in TARGET 2), and a significantly great-
er proportion of patients in the rifaximin group 
had relief with respect to the individual compo-
nents of this end point (Fig. 3A).
Efficacy during the Entire Study Period 
(Months 1 through 3)
Durability of Response on the Basis of Weekly 
Assessment
In analyses of the monthly response evaluated on 
the basis of weekly assessments, more patients 
in the rifaximin group than in the placebo group 
in both studies had adequate relief of global IBS 
symptoms within the first month, with continued 
relief during the first 2 months and during all 3 
months in both studies (P = 0.05 in TARGET 1, 
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studies combined, for relief during all 3 months) 
(Fig. 3B). With respect to IBS-related bloating, in 
TARGET 1, significantly more patients in the ri-
faximin group than in the placebo group had 
adequate relief in the first month, with contin-
ued relief during the first 2 months, but there 
were no significant between-group differences 
with respect to relief during all 3 months; in 
TARGET 2, significant benefits of rifaximin were 
seen with respect to IBS-related bloating for all 
3 months (P = 0.10 in TARGET 1, P = 0.003 in 
TARGET 2, and P = 0.001 in the two studies com-
bined, for relief during all 3 months) (Fig. 3B). The 
percentages of patients in each group with ade-
quate relief of global IBS symptoms in TARGET 1 
and TARGET 2 are provided in Figure 4, and in 
Figure 1A and 1B in the Supplementary Appendix.
Durability of Response on the Basis of Daily Assessment
The analyses of monthly response evaluated on 
the basis of daily assessments also support a du-
rable response to rifaximin in patients with IBS 
over the course of 3 months. Patients treated 
with rifaximin, as compared with patients who 
received placebo, had adequate relief of global 
IBS symptoms during the entire 3 months of the 
study (P = 0.003 in TARGET 1, P = 0.01 in TARGET 
2, and P<0.001 in the two studies combined) and 
of IBS-related bloating (P = 0.01 in TARGET 1, 
P<0.001 in TARGET 2, and P<0.001 in the two 
studies combined) (Fig. 3B).
An analysis of the monthly response evaluated 
on the basis of daily assessments of IBS-related 
abdominal pain and discomfort showed that 
significantly more patients in the rifaximin group 
than in the placebo group had relief for the en-
tire 3 months (P = 0.05 in TARGET 1, P = 0.04 in 
TARGET 2, and P = 0.01 in the two studies com-
bined) (Fig. 3B). An analysis of the monthly re-
sponse evaluated on the basis of the assessment 
of the composite end point of abdominal pain 
and stool consistency also showed a significant 
benefit with rifaximin as compared with placebo 
(P = 0.04 in TARGET 1, P = 0.01 in TARGET 2, and 
P = 0.001 in the two studies combined) (Fig. 3B).
The mean improvement from baseline in daily 
symptom scores (global IBS symptoms, IBS-relat-
ed bloating, IBS-related abdominal pain or dis-
comfort, stool consistency, and the percentage 
of days with stool urgency) was greater for the 
patients who received rifaximin than for the pa-
tients who received placebo (Fig. 2 through 6 in 
the Supplementary Appendix).
Responsiveness and Construct Validity 
of Patient-Reported Outcomes
The response of patients with respect to adequate 
relief of global IBS symptoms and of IBS-related 
bloating was consistent with the response with 
respect to other IBS-related assessments. In addi-
tion, patients who had adequate relief of global 
IBS symptoms and of IBS-related bloating had 
greater improvements in daily symptom-severity 
scores than did patients who did not have ade-
quate relief, regardless of study group, during 
each week in each study (P<0.001).
We tested the validity of using assessments of 
global IBS symptoms to measure changes in IBS 
symptoms by examining the correlation between 
these measures and changes in daily severity 
scores and bowel function; the results support 
the validity and usefulness of the primary end 
point of global IBS symptoms. Evidence for con-
vergent validity (Spearman’s correlation of 0.40 or 
higher) was observed between weekly adequate 
relief of global IBS symptoms and measures of 
daily symptom severity and bowel function.
Safety
The safety profile of rifaximin was similar to 




































Figure 4. Percentage of Patients with Adequate Relief of Global IBS Symptoms 
in the TARGET 1 and TARGET 2 Studies Combined.
Adequate relief was defined as self-reported relief from symptoms for at 
least 1 week of every 2-week period. The P value was calculated on the basis 
of a longitudinal data analysis with the use of a generalized-estimating-
equation model, with fixed effects of treatment, analysis center, and week. 
Similar figures for the individual TARGET 1 and TARGET 2 trials are shown 
in the Supplementary Appendix.
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were recorded in 10 patients in the rifaximin 
group (1.6%) and 15 patients in the placebo group 
(2.4%). There were no cases of Clostridium difficile–
associated diarrhea or ischemic colitis. No deaths 
were reported.
Discussion
Treating IBS is important because the symptoms 
cause substantial impairment in health-related 
quality of life, leading to increased use of health 
resources and reduced work productivity.17-20 
These two phase 3 studies showed that a short 
course of rifaximin leads to sustained ameliora-
tion of the symptoms of IBS without constipation 
in a subgroup of affected patients.
The antibiotic effect of rifaximin is the pre-
sumed mechanism for its sustained beneficial 
effects in patients with IBS. A response to anti-
biotic therapy in patients with IBS has been 
shown to correlate with normalization of the 
results of lactulose hydrogen breath tests.8,13 
However, there is debate about which antibiotic-
related effect is most important. On the basis of 
existing data, there are three reasonable explana-
tions: rifaximin affects gut bacteria and reduces 
bacterial products that negatively affect the host, 
the effect on gut flora reduces local mucosal 
engagement of bacteria such as the immune re-
sponses of the host, or the antibiotic alters both 
the bacteria and the host response. Whatever the 
final pathway, the durable effects suggest that 
rifaximin is affecting an underlying cause of IBS 
that is linked to an alteration in the intestinal 
microbiota.6,7,21,22 Some patients in both of our 
studies did not have a response to treatment, a 
finding that is consistent with the results of 
other placebo-controlled clinical trials involving 
patients with IBS23-25 and that may reflect differ-
ences in the underlying cause of the symptoms.
Similar percentages of patients in the rifaxi-
min group and in the placebo group had adverse 
events. In this short-term study, the incidence of 
infections was similar in the two groups, and 
there were no cases of C. difficile–associated diar-
rhea or ischemic colitis.
In summary, the results of these two phase 3 
studies showed that treatment with rifaximin at 
a dose of 550 mg three times daily for 14 days 
provides better relief of symptoms of IBS than 
does placebo for up to 10 weeks after comple-
tion of therapy.
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Headache 38 (6.1) 42 (6.6)
Upper respiratory tract infection 35 (5.6) 39 (6.2)
Abdominal pain 29 (4.6) 35 (5.5)
Nausea 27 (4.3) 24 (3.8)
Diarrhea 27 (4.3) 22 (3.5)
Nasopharyngitis 19 (3.0) 34 (5.4)
Sinusitis 17 (2.7) 16 (2.5)
Vomiting 15 (2.4) 9 (1.4)
Bronchitis 13 (2.1) 17 (2.7)
Cough 13 (2.1) 9 (1.4)
Flatulence 10 (1.6) 14 (2.2)
Back pain 10 (1.6) 15 (2.4)
Pharyngolaryngeal pain 9 (1.4) 15 (2.4)
Serious adverse events‡
Chest pain 1 (0.2) 2 (0.3)
Breast cancer 1 (0.2) 1 (0.2)
Cholecystitis or acute cholecystitis 0 2 (0.3)
Adverse events possibly related to infection§
Upper respiratory tract infection 35 (5.6) 39 (6.2)
Viral gastroenteritis 7 (1.1) 8 (1.3)
Gastroenteritis 6 (1.0) 3 (0.5)
Cellulitis 3 (0.5) 1 (0.2)
Pneumonia 1 (0.2) 5 (0.8)
Viral infection 1 (0.2) 4 (0.6)
* Values are pooled data from the TARGET 1 and TARGET 2 studies. Adverse 
events are listed in descending order of frequency in the rifaximin group.
† The adverse events listed were reported in 2% or more of the patients in ei-
ther treatment group.
‡ The serious adverse events listed were reported in at least 2 of the patients in 
any treatment group.
§ The listed adverse events possibly related to infections are known side effects 
of the use of systemic antibiotics as a drug class, as well as known effects of 
rifaximin.
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